London Mayor calls Donald Trump a ‘20th-century fascist’

Islamabad/Dhaka, May 25: The coronavirus pandemic and lockdowns coupled with travel restrictions and social distancing norms have muted the Eid celebrations in Pakistan and Bangladesh as worshippers in the two Muslim-majority countries marked the end of Ramzan in strictly-regulated prayer congregations.

A large number of people in the two countries were forced to stay indoors on the occasion of Eid al-Fitr, marking the end of the fasting month of Ramzan, due to the fears of contracting the novel coronavirus which has killed nearly 3.5 lakh people and infected over 5.4 million across the world.

In Pakistan, the government has issued strict instructions to observe social distancing while offering Eid prayers and asked people to avoid visiting relatives and hosting parties.

As the railways remained closed, many people could not travel to their hometowns for the most important festival.

Eid congregations were held at open places, mosques and Eidgahs in all major cities and towns while following strict standard operating procedures (SOPs) of social distancing and other precautionary measures. But in some areas, the people did not adhere to the SOPs and were seen thronging to their favourite shops to celebrate Eid.

Pakistan Prime Minister's Special Assistant on Health Zafar Mirza on Friday said the deadly infection would continue to multiply if precautions are not taken.

Earlier this month, the government announced the lifting of the countrywide lockdown imposed to curb the spread of the COVID-19 in phases, even as infections continued to rise in the country.

Pakistan's coronavirus cases on Monday reached 56,349 with 1,748 new patients while the death toll climbed to 1,167 after 34 people lost their lives in the last 24 hours.

The trajectory showed that the number was steadily going up with authorities fearing a rise in cases in the wake of the easing of lockdown before Eid.

But Prime Minister Imran Khan cited the economic havoc the virus restrictions had wreaked on citizens as the reason behind the decision to ease the restrictions.

He urged Pakistanis to forgo the traditional Eid festivity in view of the hundreds of fatalities caused by the coronavirus and the lives lost in Friday's plane crash in Karachi.

Ninety-seven people, including nine children, were killed and two passengers miraculously survived a fiery crash when a Pakistan International Airlines plane with 99 travellers on board plunged into a densely populated residential area near the Jinnah International Airport.

Most of the victims were travelling home to celebrate Eid.

In Bangladesh, millions of Muslims joined the strictly-regulated prayer congregations across the country.

Thousands of worshippers attended the prayer services at the Baitul Mukarram National Mosque in Dhaka while following the health and social distancing protocols to limit the spread of the coronavirus, bdnews24.com reported.

Despite the government directive for children and senior citizens not to participate in Eid prayers, many children and people aged over 60 attended the Eid prayers. Although social distancing rules were maintained to a large extent, people were seen flouting the norms, the report said.

As per the government order, no Eid congregation will be held in an open space, but people can perform the Eid prayers in mosques. However, everyone coming to the mosques for prayer must wear a mask, follow social distancing and other hygiene rules, said Islamic Foundation Secretary Kazi Nurul Islam.

On Sunday, Bangladesh reported 28 new fatalities, the highest single-day increase, bringing the death toll to 480.

The number of coronavirus cases in the country rose to 33,610 after 1,532 people tested positive on Sunday.

Melbourne, Apr 10: Scientists have identified six drug candidates from more than 10,000 compounds that may help treat COVID-19.

The research, published in the journal Nature, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

"Currently there are no targeted therapeutics or effective treatment options for COVID-19," said Professor Luke Guddat from the University of Queensland in Australia.

"In order to rapidly discover lead compounds for clinical use, we initiated a programme of high-throughput drug screening, both in laboratories and also using the latest computer software to predict how different drugs bind to the virus," Guddat said.

The project targeted the main COVID-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication, the researchers said.

This makes it an attractive drug target for this virus, and as people don't naturally have this enzyme, compounds that target it are likely to have low toxicity, they said.

"We add the drugs directly to the enzyme or to cell cultures growing the virus and assess how much of each compound is required to stop the enzyme from working or to kill the virus. If the amount is small, then we have a promising compound for further studies," said Guddat.

After assaying thousands of drugs, researchers found of the six that appear to be effective in inhibiting the enzyme, one is of particular interest.

"We're particularly looking at several leads that have been subjected to clinical trials including for the prevention and treatment of various disorders such as cardiovascular diseases, arthritis, stroke, atherosclerosis and cancer," Guddat said.

Researchers said compounds that are already along the pipeline to drug discovery are preferred, as they can be further tested as antivirals at an accelerated rate compared to new drug leads that would have to go through this process from scratch.

"With continued and up-scaled efforts we are optimistic that new candidates can enter the COVID-19 drug discovery pipeline in the near future," Guddat said.

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.